EMERYVILLE, Calif., Aug. 8 /PRNewswire-FirstCall/ -- Bionovo, Inc. , a pharmaceutical company focused on the discovery and development of safe and effective drugs in the areas of women’s health and cancer, announced today that Tom Chesterman, SVP and CFO of Bionovo, will be presenting at the 27th Annual Canaccord Adams Global Growth Conference in Boston. The presentation is scheduled to begin at 1:30 PM ET on Wednesday, August 8, 2007 at the InterContinental Hotel in Boston.
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women’s health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for the treatment of menopausal symptoms and in a trial of 217 postmenopausal women, MF101 at 10 grams/day was more effective than placebo at reducing hot flashes. In addition, MF101 was proven to be extremely safe and very well tolerated. BZL101 is in Phase 1/2 clinical trials for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. Bionovo is developing its products in close collaboration with leading U.S. academic research centers, including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Company Contacts: Bionovo, Inc. Tom Chesterman, SVP & CFO Tel: 510.420.4189 tchesterman@bionovo.com Media Katherina Audley Tel: 415.847.7295 katherina.audley@bionovo.com
Bionovo, Inc.
CONTACT: Tom Chesterman, SVP & CFO, +1-510-420-4189,tchesterman@bionovo.com, or media, Katherina Audley, +1-415-847-7295,katherina.audley@bionovo.com, both of Bionovo, Inc.
Web site: http://www.bionovo.com/
